No products in the cart
Receptor Grade IGF-1 LR3 (100mcg)
Receptor Grade IGF-1 LR3 peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is a Receptor Grade IGF-1 LR3 Peptide?
Receptor Grade IGF-1 LR3 peptide is a prime research reagent used in studies for cellular growth, IGF receptors, and IGF binding proteins. It appears to be more powerful than rH IGF-1 and Media Grade IGF-1 LR3 in-vitro because of the apparent significant improvement in its biological activity (since it exhibits a stronger affinity for the IGF receptor). This enhanced biological activity distinguishes between Receptor Grade IGF-1 LR3 and Media Grade (standard) IGF-1 LR3. Media grade IGF-1 LR3 is routinely used in commercial cell culture compared to mammalian cell culture. It is also used as a research reagent (at an economical cost) for studies where biological potency is not crucial. Receptor Grade IGF-1 LR3 should be the reagent of choice to achieve optimum results when performing any animal study, in-vitro cell-based assays, and commercial production. Growth of mammalian cells in the presence of low concentrations of Long R3 IGF-1 appears to result in better productivity than standard concentrations of insulin and/or standard IGF-1. Researchers report that the peptide “demonstrated equivalent or better performance using two recombinant CHO cell lines.” IGF-1 LR3 may be more capable of inducing the type 1 IGF receptor, promoting an elevated level of intracellular signaling, cellular proliferation, and apoptosis inhibition.
Receptor Grade IGF-1 LR3 may be biologically more potent than standard IGF-1 LR3, in-vitro.
Receptor Grade IGF-1 LR3 Specifications
Molecular Weight: 9,111 da
Sequence: MFPAMP LSSLF VNGPR TLCGA ELVDA LQFVC GDRGF YFNKP TGYGS SSRRA PQTGIV DECCFR SCDLRR LEMY CAPLK PAKSA
CAS Number: 946870-92-4
IGFB Binding and Biological Activity of IGF-1 LR3
The peptide appears to bring about a more pronounced effect than IGF-1 by resisting the association of IGFB. The prolonged duration of action may help mediate the same biological effects while using smaller doses of the receptor. Certain IGF-1 derivatives, including the GPE derivative, comprising only the last three N-terminal amino acids of the IGF-1 protein, have demonstrated potentially therapeutic effects in neurological damages such as stroke. However, the majority of the research aimed to unravel the effects of IGF-1 derivatives has been executed in non-human animal models or cell cultures.
Insulin-Like Growth Factor Receptor Interactions
Naturally produced IGF-1 hormones interact with at least two cell surface receptors: the IGF-1 receptor (IGF-1R) and the insulin receptor. The researchers also note that “IR and IGF1R act as identical portals to the regulation of gene expression, with differences between insulin and IGF-1 effects due to a modulation of the amplitude of the signal created by the specific ligand-receptor interaction.” The IGF-1R is referred to as the “physiologic” receptor due to its significantly higher affinity (approximately 100 times higher) for IGF-1 as compared to the insulin receptor. The association of IGF-1 and IGF-1R apparently leads to changes in metabolism, prevention of cell death (apoptosis), promotion of cell growth (hypertrophy), differentiation and cell division (hyperplasia), normal development, and even malignant growth. IGF-1R has been researched for its involvement in diverse types of cancer, such as prostate, breast, and lung cancer. IGF-1 also appears to stimulate insulin receptors and activate them, thereby promoting glucose uptake from the bloodstream by cells. IGF-1 displays a three-fold influence on muscle cells. At the onset, IGF-1 may promote an increase in the number of muscle cells, also known as hyperplasia. Secondly, IGF-1 appears to influence the life span of satellite cells of the skeletal muscles. Satellite cells provide nutritional support to muscle cells, thereby helping them to operate efficiently. IGF-1 thus may help to build muscle tissue by improving the lifespan of these cells. Finally, IGF-1 appears to promote the differentiation of myoblasts. In other words, it may encourage the commitment of stem cell progeny from non-specific pluripotent stem cells to dedicated muscle tissue. To conclude, IGF-1 may improve muscle development by enhancing the rate at which generic stem cells are transformed into muscle cells.
- Thomas, James N., and Victor Fung. “Comparison of long R3 IGF-1 with insulin in the support of cell growth and recombinant protein expression in CHO cells.” Animal Cell Technology. Butterworth-Heinemann, 1994. 91-95.
- Assefa, Biruhalem, et al. “Insulin-like growth factor (IGF) binding protein-2, independently of IGF-1, induces GLUT-4 translocation and glucose uptake in 3T3-L1 adipocytes.” Oxidative Medicine and Cellular Longevity 2017 (2017).
- Boucher J, Tseng YH, Kahn CR. Insulin and insulin-like growth factor-1 receptors act as ligand-specific amplitude modulators of a common pathway regulating gene transcription. J Biol Chem. 2010 May 28;285(22):17235-45. doi: 10.1074/jbc.M110.118620. Epub 2010 Apr 1. PMID: 20360006; PMCID: PMC2878077.
- Shanmugalingam T, Bosco C, Ridley AJ, Van Hemelrijck M. Is there a role for IGF-1 in the development of second primary cancers? Cancer Med. 2016 Nov;5(11):3353-3367. doi: 10.1002/cam4.871. Epub 2016 Oct 13. PMID: 27734632; PMCID: PMC5119990.
- Yoshida T, Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020 Aug 26;9(9):1970. doi: 10.3390/cells9091970. PMID: 32858949; PMCID: PMC7564605.
- Aboalola D, Han VKM. Different Effects of Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor-2 on Myogenic Differentiation of Human Mesenchymal Stem Cells. Stem Cells Int. 2017;2017:8286248. doi: 10.1155/2017/8286248. Epub 2017 Dec 14. PMID: 29387091; PMCID: PMC5745708.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.